Chemours fell 22% lower on Wednesday and Dupont 1.8% after Dupont was found liable for a man’s testicular cancer in a test case involving 3,500 lawsuits. According to two sources familiar with the matter, the jury awarded the man $5.1 million. Though Dupont was found liable, its spinoff Chemours will bear the cost but said … Continue reading “Testicular Cancer Hits Chemours (CC) Shares Hard”
